iPS cell modeling of cardiometabolic diseases.
Cardiometabolic diseases encompass simple monogenic enzyme deficiencies with well-established pathogenesis and clinical outcomes to complex polygenic diseases such as the cardiometabolic syndrome. The limited availability of relevant human cell types such as cardiomyocytes has hampered our ability to adequately model and study pathways or drugs relevant to these diseases in the heart. The recent discovery of induced pluripotent stem (iPS) cell technology now offers a powerful opportunity to establish translational platforms for cardiac disease modeling, drug discovery, and pre-clinical testing. In this article, we discuss the excitement and challenges of modeling cardiometabolic diseases using iPS cell and their potential to revolutionize translational research.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. knakamura@partners.org
Kenta
K
Nakamura
Ken-ichi
K
Hirano
Sean M
SM
Wu
D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D006009:Glycogen Storage Disease Type II / Q000201:enzymology; D052120:Glycogen Storage Disease Type IIb / Q000201:enzymology; D006331:Heart Diseases / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D016113:Ichthyosiform Erythroderma, Congenital / Q000201:enzymology; D057026:Induced Pluripotent Stem Cells / Q000201:enzymology*; D008052:Lipid Metabolism, Inborn Errors / Q000201:enzymology; D008659:Metabolic Diseases / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology; D009135:Muscular Diseases / Q000201:enzymology; D032383:Myocytes, Cardiac / Q000201:enzymology*; D010641:Phenotype
D055372:AMP-Activated Protein Kinases